DK3612174T3 - Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af sygdomme associeret med reduceret cftr-funktion - Google Patents
Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af sygdomme associeret med reduceret cftr-funktion Download PDFInfo
- Publication number
- DK3612174T3 DK3612174T3 DK18717946.0T DK18717946T DK3612174T3 DK 3612174 T3 DK3612174 T3 DK 3612174T3 DK 18717946 T DK18717946 T DK 18717946T DK 3612174 T3 DK3612174 T3 DK 3612174T3
- Authority
- DK
- Denmark
- Prior art keywords
- treatment
- methods
- pharmaceutical compositions
- diseases associated
- cftr function
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17305459 | 2017-04-21 | ||
PCT/EP2018/060145 WO2018193075A1 (en) | 2017-04-21 | 2018-04-20 | Methods and pharmaceutical compositions for the treatment of diseases associated with reduced cftr function |
Publications (1)
Publication Number | Publication Date |
---|---|
DK3612174T3 true DK3612174T3 (da) | 2023-05-08 |
Family
ID=58640804
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK18717946.0T DK3612174T3 (da) | 2017-04-21 | 2018-04-20 | Fremgangsmåder og farmaceutiske sammensætninger til behandlingen af sygdomme associeret med reduceret cftr-funktion |
Country Status (4)
Country | Link |
---|---|
US (1) | US11458118B2 (da) |
EP (1) | EP3612174B1 (da) |
DK (1) | DK3612174T3 (da) |
WO (1) | WO2018193075A1 (da) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11534423B2 (en) * | 2019-01-03 | 2022-12-27 | Washington University | Methods and compositions for improving exercise endurance, performance, or tolerance |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6566131B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of Smad6 expression |
US6410323B1 (en) | 1999-08-31 | 2002-06-25 | Isis Pharmaceuticals, Inc. | Antisense modulation of human Rho family gene expression |
US6107091A (en) | 1998-12-03 | 2000-08-22 | Isis Pharmaceuticals Inc. | Antisense inhibition of G-alpha-16 expression |
US5981732A (en) | 1998-12-04 | 1999-11-09 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-13 expression |
US6046321A (en) | 1999-04-09 | 2000-04-04 | Isis Pharmaceuticals Inc. | Antisense modulation of G-alpha-i1 expression |
US6723553B2 (en) | 2000-06-27 | 2004-04-20 | Biovitrum Ab | Promoter sequences |
US6365354B1 (en) | 2000-07-31 | 2002-04-02 | Isis Pharmaceuticals, Inc. | Antisense modulation of lysophospholipase I expression |
US6566135B1 (en) | 2000-10-04 | 2003-05-20 | Isis Pharmaceuticals, Inc. | Antisense modulation of caspase 6 expression |
HUE038850T2 (hu) | 2012-05-25 | 2018-11-28 | Univ California | Eljárások és kompozíciók cél-DNS RNS-irányított módosításához és transzkripció RNS-irányított modulálásához |
US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
-
2018
- 2018-04-20 US US16/606,236 patent/US11458118B2/en active Active
- 2018-04-20 WO PCT/EP2018/060145 patent/WO2018193075A1/en active Application Filing
- 2018-04-20 DK DK18717946.0T patent/DK3612174T3/da active
- 2018-04-20 EP EP18717946.0A patent/EP3612174B1/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3612174A1 (en) | 2020-02-26 |
US20200121642A1 (en) | 2020-04-23 |
EP3612174B1 (en) | 2023-02-22 |
WO2018193075A1 (en) | 2018-10-25 |
US11458118B2 (en) | 2022-10-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK3717471T3 (da) | Nye forbindelser og lægemiddelsammensætninger heraf til behandling af sygdomme | |
DK3402499T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af type 1 diabetes | |
DK3445388T3 (da) | Materialer og fremgangsmåder til behandling af hæmoglobinopatier | |
DK3889145T3 (da) | 8-cyano-5-piperidino-quinoliner som TLR7/8-antagonister og anvendelser deraf til behandling af immunsygdomme | |
DK3173092T3 (da) | Rna-holdig sammensætning til behandling af tumorsygdomme | |
DK3402888T3 (da) | Middel og fremgangsmåder til behandling af hbv | |
DK3185876T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurologiske lidelser | |
DK3102673T3 (da) | Fremgangsmåder og sammensætninger til behandling af beta-talassæmi | |
IL255109A0 (en) | New dihydropyridoisoquinolinones and their pharmaceutical preparations for the treatment of inflammatory disorders | |
DK3303339T3 (da) | Pde9-inhibitorer med imidazotriazinonskelet og imidazopyrazinonskelet til behandling af perifere sygdomme | |
DK3487505T3 (da) | Indgivelse og dosering af diaminophenothiaziner | |
DK3277270T3 (da) | Sammensætninger og fremgangsmåder til behandling af anæmi | |
DK3478679T3 (da) | 5,7-dihydro-pyrrolo-pyridin-derivater til behandling af neurologiske og neurodegenerative sygdomme | |
DK3189074T3 (da) | Sammensætninger og metoder til behandling og forebyggelse af inflammation | |
DK3386523T3 (da) | Bifidobacterium longum til behandling af fedme og associerede metabolske sygdomme | |
DK3242947T3 (da) | Genterapi og elektroporese til behandling af maligniteter | |
DK3255042T3 (da) | Heterocyklisk forbindelse og farmaceutisk sammensætning omfattende samme | |
DK3380525T3 (da) | Farmaceutiske formuleringer og fremgangsmåder til anvendelse deraf | |
DK3468604T3 (da) | Farmaceutiske kombinationer til behandling af cancer | |
DK3328864T3 (da) | Terapeutiske forbindelser og sammensætninger til behandling af sociale forstyrrelser og stofmisbrugsforstyrrelser | |
DK3200748T3 (da) | Sammensætninger og fremgangsmåder til behandling og profylakse af infektioner på operationssted | |
DK3522873T3 (da) | Sammensætninger og fremgangsmåder til behandlingen af xerostomi | |
DK3403674T3 (da) | Farmaceutiske sammensætninger til behandling af smerte | |
DK3139963T3 (da) | Konjugater og prodrugs til behandling af cancer og inflammatoriske sygdomme | |
DK3122743T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme |